Core Insights - The core viewpoint of the article is that the market for laparoscopic surgical robots in China is experiencing a structural shift, with domestic brands, particularly Jingfeng Medical, gaining significant traction against the dominant Da Vinci system, indicating a growing competitive landscape [3][4][20]. Group 1: Overall Market Landscape - In 2025, the laparoscopic surgical robot market in China continued to show steady growth despite overall pressure in the medical device market [3]. - Da Vinci remains the market leader, but domestic brands have begun to establish a foothold, with eight domestic manufacturers achieving public bidding success [3][4]. - Domestic brands collectively won 47 bids, accounting for approximately 52% of the total, with Jingfeng Medical leading with 16 bids (34% of the total) [3][4]. Group 2: Manufacturer Performance - The top domestic manufacturers include Jingfeng Medical, Weichuang Robotics, and Sizhe Rui, which are emerging as significant players in the market [4]. - The bidding data indicates a clear differentiation among domestic manufacturers in terms of bidding quantity and pricing, reflecting varying stages of development and capabilities [5][9]. Group 3: Bidding Quantity and Price Structure - In 2025, the total number of bids and the total bid amounts show a concentrated structure, with Jingfeng Medical, Weichuang Robotics, and Sizhe Rui significantly outperforming other manufacturers [9]. - The average bid price for Da Vinci was 1,817,000 RMB, while Jingfeng Medical's average was 1,453,000 RMB, indicating a competitive pricing strategy among domestic brands [6][9]. Group 4: Hospital Selection Behavior - The majority of bids were awarded to tertiary hospitals, indicating that these institutions are the primary market for laparoscopic surgical robots, reflecting a judgment of capability rather than policy-driven procurement [11][14]. - There is a noticeable trend of hospitals making multiple bids within the same year, suggesting a shift from merely introducing equipment to expanding its use based on real-world experience [15][16]. - Domestic manufacturers are increasingly entering various levels of hospitals, with successful bids in multiple regions, indicating a move towards broader market acceptance [16][20]. Group 5: Conclusion - The data from 2025 indicates a significant transition in the market, where continuous bidding and cross-regional bids are becoming new benchmarks for success, moving beyond initial equipment introduction to sustained usage [17][20].